(Q45279435)

11 December 2017

title

No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis (English)

1 reference

primary biliary cholangitis

11 December 2017

main subject

0 references

author name string

Karin Dilger

1

1 reference

11 December 2017

Annette Denk

2

1 reference

11 December 2017

Malte H J Heeg

3

1 reference

11 December 2017

Ulrich Beuers

4

1 reference

11 December 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

11 December 2017

1 reference

11 December 2017

volume

41

1 reference

11 December 2017

issue

3

1 reference

11 December 2017

page(s)

595-602

1 reference

Effects of long-term rifampicin administration in primary biliary cirrhosis

11 December 2017

cites work

1 reference

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited

21 January 2018

1 reference

7 January 2021

Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.

1 reference

7 January 2021

Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases

1 reference

7 January 2021

Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial

1 reference

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

7 January 2021

Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver

1 reference

7 January 2021

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

1 reference

7 January 2021

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

7 January 2021

Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group

1 reference

7 January 2021

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

1 reference

7 January 2021

Ursodeoxycholic acid for primary biliary cirrhosis

1 reference

7 January 2021

Cytochrome P-450 3A4: regulation and role in drug metabolism

1 reference

7 January 2021

In vitro and in vivo drug interactions involving human CYP3A.

1 reference

7 January 2021

Genetic variability in CYP3A5 and its possible consequences.

1 reference

7 January 2021

The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

1 reference

7 January 2021

Bile acid structure and selective modulation of murine hepatic cytochrome P450-linked enzymes

1 reference

7 January 2021

Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP [correction of CXP] and preservation of BSEP activities

1 reference

7 January 2021

Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450.

1 reference

7 January 2021

Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4.

1 reference

7 January 2021

Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial

1 reference

7 January 2021

Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis

1 reference

7 January 2021

Urinary 6?-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals

1 reference

7 January 2021

Simultaneous determination of urinary free cortisol and 6β-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity

1 reference

7 January 2021

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

7 January 2021

Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use.

1 reference

7 January 2021

Sex is a major determinant of CYP3A4 expression in human liver

1 reference

7 January 2021

The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity

1 reference

7 January 2021

Review article: pruritus in cholestatic and other liver diseases

1 reference

7 January 2021

Extrahepatic manifestations of cholestasis

1 reference

7 January 2021

Regulation of cyp3a gene transcription by the pregnane x receptor

1 reference

7 January 2021

Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin

1 reference

7 January 2021

The human bile salt export pump: characterization of substrate specificity and identification of inhibitors

1 reference

7 January 2021

Pharmacokinetic interactions with rifampicin : clinical relevance

1 reference

7 January 2021

Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin

1 reference

7 January 2021

Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens

1 reference

7 January 2021

Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein

1 reference

7 January 2021

Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis.

1 reference

7 January 2021

Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin

1 reference

7 January 2021

The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.

1 reference

7 January 2021

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20568

1 reference

11 December 2017

1 reference